Advanced Enzyme Technologies Ltd · ADVENZYMES
—
—
—
—
—
₹142 Cr
₹139 Cr
₹147 Cr
₹158 Cr
₹161 Cr
₹158 Cr
₹155 Cr
₹146 Cr
₹169 Cr
₹167 Cr
₹186 Cr
₹185 Cr
₹172 Cr
₹203 Cr
—
20-quarter listed-company comparison
Seeds/Tissue Culture/Bio Technology Stocks in India
Seeds/Tissue Culture/Bio Technology: Rossari Biotech Ltd owns the largest revenue base AND the fastest current growth.
01 · the index people search for
Nifty Seeds/Tissue Culture/Bio Technology Index — Constituents & Performance
The Seeds/Tissue Culture/Bio Technology companies below are the listed Indian Seeds/Tissue Culture/Bio Technology universe this page tracks — the same constituent set people search for as the Nifty Seeds/Tissue Culture/Bio Technology index. Every figure is equal-weighted across those companies, so one large constituent cannot set the reading. Each number carries its own as-of date.
02 · the sector itself · before any single company
How has Seeds/Tissue Culture/Bio Technology moved against NIFTY 500?
The line below covers up to 5.2 years and opens on the 5Y view; the buttons cut it shorter. Over the most recent two of them this sector is 43% behind NIFTY 500. Earnings across its companies grew 5% on average over the last four reported quarters — close to flat.
ASLEEP · 1y −27.6%✓Price down, no fundamental support0 of 3 companies ahead of NIFTY 500 by 5% or more over three months
RS — · 1/3 >200d (+0) · 0/3 lead (−2) · EPS 2/3↑
Seeds/Tissue Culture/Bio Technology, equal-weighted, based at 200
NIFTY 500, same base, same start
trailing 12-month earnings per share rising
falling
Seeds/Tissue Culture/Bio Technology, equal-weighted, based at 200
NIFTY 500, same base, same start
trailing 12-month earnings per share rising
falling
Seeds/Tissue Culture/Bio Technology, equal-weighted, based at 200
NIFTY 500, same base, same start
trailing 12-month earnings per share rising
falling
Both lines start at 200 in the same week, so the distance between them is the whole story: the sector line is an equal-weighted index of its 3 companies. The bars underneath are trailing 12-month earnings per share, one bar per reported quarter, each member rebased to 100 at the start and the sector taking the median — so a price line pulling away from flat bars is a re-rating, not earnings. A bar turns red when that figure is lower than the quarter before. Rules are fixed and applied identically everywhere on this site: ahead by 5% or more over three months, or behind by 20% or more over a year while earnings grew 20% or more. Hover any point to read both values and the gap. This is a description of what the numbers did, not advice.
03 · sector relative strength, before individual stocks
Is Seeds/Tissue Culture/Bio Technology outperforming NIFTY 500?
Seeds/Tissue Culture/Bio Technology has underperformed NIFTY 500 by 31.9% over the last 52 weeks. Over 13 weeks the gap is a shortfall of 7%. 0 of 3 covered companies currently beat NIFTY on Mansfield relative strength, so leadership inside the sector is broad. Advanced Enzyme Technologies Ltd is the strongest against the sector itself at +12.2%.
-7.0%Sector vs NIFTY 500 · 13 weeks
-31.9%Sector vs NIFTY 500 · 52 weeks
0/3Stocks leading NIFTY 500
2/3Stocks leading sector
Sector metric: — as of latest available · unclassified · direction unavailable.
The central tension: current leadership is concentrated, so durability matters more than rank.
Start with scale. Then earnings trajectory. Then business quality. Only after those three agree should price leadership carry much weight.
Bottom line
Seeds/Tissue Culture/Bio Technology has underperformed NIFTY 500 by 31.9% over 52 weeks and 7% over 13 weeks. 0 of 3 covered companies beat NIFTY on Mansfield relative strength, while 2 of 3 beat the sector itself. Rossari Biotech Ltd leads with revenue of ₹2,550 crore, based on 3 of 3 comparable companies through Jun 2026.
Companies
3
complete canonical membership
Combined market value
₹7.2K Cr
Advanced Enzyme Technologies Ltd
Revenue growing
2/3
positive TTM year-on-year growth
Beating NIFTY 500
0/3
positive Mansfield relative strength
Comparing 3 of 3
04 · research priority, made explicit
4-Factor Sector Score
An additive sector-relative research score. The four displayed point contributions always equal the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or stale evidence is absorbed inside the affected factor, never applied as a hidden adjustment.
Growth & earnings · 35%Capital efficiency · 25%Valuation · 20%Relative strength · 20%
Advanced Enzyme Technologies Ltd has the strongest current balance of earnings trajectory, business quality, valuation and price confirmation, with 75.1% evidence confidence.
How this score is built, and what the marks mean
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Advanced Enzyme Technologies LtdADVENZYMES | 65.8/100Favorable setup75% evidence | ASLEEP | 27.8/35 Revenue 17.1% · PAT 29.1% · OPM change 4 pp 83% evidence | 15.5/25 ROCE 14% · OPM 31% 76% evidence | 12.0/20 P/E 22.8× · PEG — 35% evidence | 10.5/20 RS sector 12.2% · RS bench -1.9% · 1Y -3.4%9 of 12 weeks ahead 100% evidence |
| Exact sum: 27.8 + 15.5 + 12 + 10.5 = 65.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Rossari Biotech LtdROSSARI | 57.0/100Mixed-positive evidence97% evidence | FADING | 20.4/35 Revenue 19.4% · PAT 11.8% · OPM change 0 pp 100% evidence | 10.4/25 ROCE 13.3% · OPM 12% 100% evidence | 12.7/20 P/E 18.5× · PEG 1.7 85% evidence | 13.5/20 RS sector 3.4% · RS bench -10.4% · 1Y -29.3%5 of 12 weeks ahead 100% evidence |
| Exact sum: 20.4 + 10.4 + 12.7 + 13.5 = 57 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Bombay Super Hybrid Seeds LtdBSHSL | 33.1/100Adverse evidence74% evidence | ASLEEP | 5.7/35 Revenue -4.1% · PAT 0.9% · OPM change -3.5 pp 83% evidence | 12.2/25 ROCE 16% · OPM 9.8% 95% evidence | 12.2/20 P/E 33.5× · PEG — 35% evidence | 3.0/20 RS sector -17.4% · RS bench -19.5% · 1Y -37.5%6 of 10 weeks ahead 70% evidence |
| Exact sum: 5.7 + 12.2 + 12.2 + 3 = 33.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
05 · what price has already done
Market action
Advanced Enzyme Technologies Ltd has the strongest one-year price move in Seeds/Tissue Culture/Bio Technology at -3.4%. It also leads on Mansfield relative strength against NIFTY at -1.9%. 0 of 3 covered companies are above zero on that measure. Every line covers 313 weekly closes through 2026-07-31.
Price and relative strength
Every company, the sector's own index and NIFTY 500 all start level on the left edge of the window, so only the distance between the lines counts — the highest line has risen the most since then, and the chart at the top of this page is drawn the same way. It opens on one year; the buttons beside it stretch that to three or five.
How far ahead of or behind NIFTY 500 each company has been running, measured against its own recent average of that comparison, so the flat line at zero IS NIFTY 500: above it the company is beating the market, below it the market is beating the company. It opens on one year.
The same measure taken against Seeds/Tissue Culture/Bio Technology itself instead of the whole market, so the flat line at zero is the sector: above it the company is beating its own peers, which is the sharper test of the two. It opens on one year.
06 · compare level, then change
Revenue Scale & Growth Durability
Rossari Biotech Ltd has the highest Revenue among the 3 Seeds/Tissue Culture/Bio Technology companies compared here, at ₹2,550 crore. Advanced Enzyme Technologies Ltd is next at ₹746 crore. The same company also holds the highest Revenue growth, at 19.4%. 3 of 3 companies report a comparable reading, the latest through Jun 2026.
What the numbers say: Rossari Biotech Ltd is the scale leader at ₹2,550 crore, 241.8% ahead of Advanced Enzyme Technologies Ltd. Rossari Biotech Ltd's growth is 19.4% from a ₹2,550 crore base, with 20 reported observations in the 20-quarter window. Treat the growth leader as an acceleration candidate, not as equally proven scale.
LeaderRossari Biotech Ltd · ₹2,550 crore
Gap241.8% versus #2 · Advanced Enzyme Technologies Ltd
Persistence8/8 recent comparable periods
Coverage3/3 companies · 48 observations
Investor read: Rossari Biotech Ltd is the scale benchmark; Rossari Biotech Ltd is the acceleration watch. Promote the challenger only if growth persists and converts into margin and returns.
This conclusion weakens if: Rossari Biotech Ltd's growth falls below Rossari Biotech Ltd's for two consecutive comparable reports while operating margin also compresses.
Revenue is compared on a common reported-currency basis. Growth is year-on-year, so seasonality does not masquerade as progress.
Revenuelargest
Revenue growthfastest growers
Revenue · company comparison
3/3 level · 3/3 change
On every company-comparison chart on this page: solid lines show level, dotted lines show change when “Both” is selected, and a missing report breaks the line rather than being invented.
All-company data · latest reported quarter
In every all-company table on this page, each figure is the company’s latest single reported quarter. The rankings above them use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
| Company | Revenue | Revenue growth | Reported |
|---|---|---|---|
| Rossari Biotech Ltd ROSSARI | ₹697 Cr | 28% | Jun 2026 |
| Advanced Enzyme Technologies Ltd ADVENZYMES | ₹203 Cr | 22% | Mar 2026 |
| Bombay Super Hybrid Seeds Ltd BSHSL⚠ unverified | ₹66 Cr | 45% | Mar 2026 |
Full 20-quarter history · every available company
Revenue · reported quarter history
Bombay Super Hybrid Seeds Ltd · BSHSL⚠ unverified
—
—
—
—
—
₹69 Cr
₹36 Cr
₹117 Cr
₹34 Cr
₹76 Cr
₹30 Cr
₹157 Cr
₹28 Cr
₹128 Cr
₹46 Cr
₹153 Cr
₹27 Cr
₹98 Cr
₹66 Cr
—
Rossari Biotech Ltd · ROSSARI
₹385 Cr
₹428 Cr
₹439 Cr
₹435 Cr
₹425 Cr
₹389 Cr
₹406 Cr
₹411 Cr
₹483 Cr
₹464 Cr
₹473 Cr
₹490 Cr
₹498 Cr
₹513 Cr
₹580 Cr
₹544 Cr
₹586 Cr
₹582 Cr
₹685 Cr
₹697 Cr
Revenue growth · reported quarter history
Advanced Enzyme Technologies Ltd · ADVENZYMES
—
—
—
—
—
—
—
—
—
13%
14%
5.4%
-7.6%
5.0%
5.7%
20%
27%
1.8%
22%
—
Bombay Super Hybrid Seeds Ltd · BSHSL⚠ unverified
—
—
—
—
—
—
—
—
—
11%
-16%
34%
-16%
67%
52%
-2.4%
-4.8%
-23%
45%
—
Rossari Biotech Ltd · ROSSARI
—
—
—
—
10%
-9.1%
-7.5%
-5.5%
14%
19%
17%
19%
3.1%
11%
23%
11%
18%
13%
18%
28%
07 · compare level, then change
Operating Economics & Margin Trend
Advanced Enzyme Technologies Ltd has the highest OPM among the 3 Seeds/Tissue Culture/Bio Technology companies compared here, at 31%. Rossari Biotech Ltd is next at 12%. The same company also holds the highest Margin change, at +4 percentage points. 3 of 3 companies report a comparable reading, the latest through Mar 2026.
What the numbers say: Advanced Enzyme Technologies Ltd leads both opm at 31% and margin change at +4 percentage points.
LeaderAdvanced Enzyme Technologies Ltd · 31%
Gap158.3% versus #2 · Rossari Biotech Ltd
Persistence3/8 recent comparable periods
Coverage3/3 companies · 58 observations
Investor read: Advanced Enzyme Technologies Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current margin change signal.
Operating margin compares operating profit with revenue. Improvement is measured in percentage points, not percentage growth.
OPMhighest
Margin changefastest expanders
Operating margin · company comparison
3/3 level · 3/3 change
All-company data · latest reported quarter
| Company | OPM | Margin change | Reported |
|---|---|---|---|
| Advanced Enzyme Technologies Ltd ADVENZYMES | 31% | +4.0 pp | Mar 2026 |
| Rossari Biotech Ltd ROSSARI | 12% | 0.0 pp | Jun 2026 |
| Bombay Super Hybrid Seeds Ltd BSHSL⚠ unverified | 9.8% | −3.5 pp | Mar 2026 |
Full 20-quarter history · every available company
OPM · reported quarter history
Advanced Enzyme Technologies Ltd · ADVENZYMES
39%
37%
31%
26%
29%
29%
32%
30%
32%
33%
35%
33%
29%
33%
27%
30%
33%
29%
31%
—
Bombay Super Hybrid Seeds Ltd · BSHSL⚠ unverified
6.3%
5.3%
8.8%
8.7%
6.5%
12%
9.3%
11%
8.7%
12%
12%
8.7%
11%
7.8%
13%
10%
15%
9.8%
9.8%
—
Rossari Biotech Ltd · ROSSARI
12%
11%
12%
13%
13%
14%
13%
14%
13%
14%
13%
13%
13%
13%
12%
12%
12%
12%
11%
12%
Margin change · reported quarter history
Advanced Enzyme Technologies Ltd · ADVENZYMES
−9.8 pp
−11.5 pp
−10.7 pp
−20.3 pp
−10.2 pp
−7.7 pp
+1.4 pp
+4.5 pp
+3.4 pp
+4.0 pp
+3.0 pp
+3.0 pp
−3.0 pp
0.0 pp
−8.0 pp
−3.0 pp
+4.0 pp
−4.0 pp
+4.0 pp
—
Bombay Super Hybrid Seeds Ltd · BSHSL⚠ unverified
+2.1 pp
+0.5 pp
−1.5 pp
+0.7 pp
+0.2 pp
+6.2 pp
+0.6 pp
+2.3 pp
+2.1 pp
+0.5 pp
+2.3 pp
−2.3 pp
+2.3 pp
−4.3 pp
+1.7 pp
+1.4 pp
+4.5 pp
+2.0 pp
−3.5 pp
—
Rossari Biotech Ltd · ROSSARI
−5.7 pp
−5.1 pp
−4.6 pp
−2.8 pp
+1.5 pp
+2.9 pp
+1.1 pp
+0.7 pp
−0.3 pp
0.0 pp
0.0 pp
−1.0 pp
0.0 pp
−1.0 pp
−1.0 pp
−1.0 pp
−1.0 pp
−1.0 pp
−1.0 pp
0.0 pp
08 · compare level, then change
Profit Scale & Acceleration
Advanced Enzyme Technologies Ltd has the highest Net profit among the 3 Seeds/Tissue Culture/Bio Technology companies compared here, at ₹173 crore. Rossari Biotech Ltd is next at ₹151 crore. The same company also holds the highest Profit growth, at 29.1%. 3 of 3 companies report a comparable reading, the latest through Mar 2026.
What the numbers say: Advanced Enzyme Technologies Ltd leads with ₹173 crore of TTM profit, 14.6% above Rossari Biotech Ltd. Advanced Enzyme Technologies Ltd shows 29.1% growth from a ₹173 crore profit base. Compare the size of the base and persistence before ranking acceleration above profit scale.
LeaderAdvanced Enzyme Technologies Ltd · ₹173 crore
Gap14.6% versus #2 · Rossari Biotech Ltd
Persistence5/8 recent comparable periods
Coverage3/3 companies · 48 observations
Investor read: Advanced Enzyme Technologies Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current profit growth signal.
Net profit is the residual after operating costs, interest and tax. Growth off a loss or near-zero base is excluded from the fastest-grower rank.
Net profitlargest
Profit growthfastest growers
Net profit · company comparison
3/3 level · 3/3 change
All-company data · latest reported quarter
| Company | Net profit | Profit growth | Reported |
|---|---|---|---|
| Advanced Enzyme Technologies Ltd ADVENZYMES | ₹45 Cr | 67% | Mar 2026 |
| Rossari Biotech Ltd ROSSARI | ₹35 Cr | 2.9% | Jun 2026 |
| Bombay Super Hybrid Seeds Ltd BSHSL⚠ unverified | ₹4 Cr | 4.5% | Mar 2026 |
Full 20-quarter history · every available company
Net profit · reported quarter history
Advanced Enzyme Technologies Ltd · ADVENZYMES
—
—
—
—
—
₹28 Cr
₹32 Cr
₹29 Cr
₹35 Cr
₹42 Cr
₹30 Cr
₹35 Cr
₹33 Cr
₹39 Cr
₹27 Cr
₹40 Cr
₹45 Cr
₹43 Cr
₹45 Cr
—
Bombay Super Hybrid Seeds Ltd · BSHSL⚠ unverified
—
—
—
—
—
₹7 Cr
₹2 Cr
₹11 Cr
₹2 Cr
₹7 Cr
₹3 Cr
₹11 Cr
₹2 Cr
₹9 Cr
₹4 Cr
₹12 Cr
₹2 Cr
₹8 Cr
₹4 Cr
—
Rossari Biotech Ltd · ROSSARI
₹26 Cr
₹23 Cr
₹24 Cr
₹29 Cr
₹24 Cr
₹26 Cr
₹29 Cr
₹29 Cr
₹33 Cr
₹34 Cr
₹34 Cr
₹35 Cr
₹35 Cr
₹32 Cr
₹34 Cr
₹34 Cr
₹37 Cr
₹33 Cr
₹46 Cr
₹35 Cr
Profit growth · reported quarter history
Advanced Enzyme Technologies Ltd · ADVENZYMES
—
—
—
—
—
—
—
—
—
50%
-6.3%
21%
-5.7%
-7.1%
-10%
14%
36%
10%
67%
—
Bombay Super Hybrid Seeds Ltd · BSHSL⚠ unverified
—
—
—
—
—
—
—
—
—
3.5%
64%
4.5%
32%
31%
35%
10%
8.2%
-14%
4.5%
—
Rossari Biotech Ltd · ROSSARI
—
—
—
—
-7.7%
13%
21%
0.0%
38%
31%
17%
21%
6.1%
-5.9%
0.0%
-2.9%
5.7%
3.1%
35%
2.9%
09 · compare level, then change
Return On Capital Employed
Bombay Super Hybrid Seeds Ltd has the highest ROCE among the 3 Seeds/Tissue Culture/Bio Technology companies compared here, at 16%. Advanced Enzyme Technologies Ltd is next at 14%. Advanced Enzyme Technologies Ltd has the highest ROCE change at +1 percentage points, so level and change sit with different companies. Its ROCE series carries 15 reported observations across the 20-quarter window.
What the numbers say: Bombay Super Hybrid Seeds Ltd leads ROCE at 16%, 2 percentage points above Advanced Enzyme Technologies Ltd. Advanced Enzyme Technologies Ltd has the strongest latest improvement at +1 percentage points. Read the leader beside the density of its reported history: a sparse high return is a candidate; a repeated high return is evidence of durability.
LeaderBombay Super Hybrid Seeds Ltd · 16%
Gap14.3% versus #2 · Advanced Enzyme Technologies Ltd
Persistence0/8 recent comparable periods
Coverage3/3 companies · 31 observations
Investor read: Bombay Super Hybrid Seeds Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current roce change signal.
ROCE asks how much operating return the business earns on the capital employed. Direction matters, but a single exceptional year should not be mistaken for durability.
ROCEhighest
ROCE changefastest improvers
Return on capital · company comparison
3/3 level · 3/3 change
Withheld from this chart: Advanced Enzyme Technologies Ltd (ADVENZYMES) — its two data sources disagree by up to 4% on reported income across 14 comparable periods, so its derived ratios are withheld. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
All-company data · latest reported quarter
| Company | ROCE | ROCE change | Reported |
|---|---|---|---|
| Bombay Super Hybrid Seeds Ltd BSHSL⚠ unverified | 25% | −5.0 pp | Mar 2026 |
| Rossari Biotech Ltd ROSSARI | 17% | +0.3 pp | Jun 2026 |
Full 20-quarter history · every available company
ROCE · reported quarter history
Bombay Super Hybrid Seeds Ltd · BSHSL⚠ unverified
29%
—
31%
—
31%
—
36%
—
36%
46%
35%
43%
31%
39%
30%
39%
28%
32%
25%
—
Rossari Biotech Ltd · ROSSARI
13%
—
13%
—
15%
—
15%
—
15%
18%
16%
19%
15%
17%
14%
16%
13%
16%
13%
17%
ROCE change · reported quarter history
Bombay Super Hybrid Seeds Ltd · BSHSL⚠ unverified
—
—
—
—
+1.3 pp
—
+5.3 pp
—
+5.7 pp
—
−1.2 pp
—
−5.9 pp
−6.9 pp
−4.2 pp
−3.7 pp
−2.2 pp
−6.4 pp
−5.0 pp
—
Rossari Biotech Ltd · ROSSARI
—
—
—
—
+2.1 pp
—
+1.5 pp
—
−0.1 pp
—
+1.0 pp
—
+0.1 pp
−1.3 pp
−2.1 pp
−2.3 pp
−2.0 pp
−1.3 pp
−1.1 pp
+0.3 pp
10 · compare level, then change
Valuation Against Growth & Quality
Rossari Biotech Ltd has the lowest PEG among the 3 Seeds/Tissue Culture/Bio Technology companies compared here, at 1.7×. The same company also holds the lowest P/E, at 18.5×. 1 of 3 companies report a comparable reading, the latest through Jun 2026. Its PEG series carries 13 reported observations across the 20-quarter window.
What the numbers say: Rossari Biotech Ltd has the lowest comparable PEG at 1.7×. Only 1 of 3 companies have earnings and growth steady enough for the ratio to mean anything, so no broad “cheapest stock” conclusion is defensible unless the current multiple, own-history position and growth durability agree.
LeaderRossari Biotech Ltd · 1.7×
GapNot enough peers
Persistence0/8 recent comparable periods
Coverage1/3 companies · 13 observations
Investor read: Treat valuation as permission to investigate, never as a standalone reason to buy.
This conclusion weakens if: The next two comparable reports reverse the current p/e signal.
PEG is shown only when earnings are positive and three-year EPS growth is between 5% and 60%. It is recomputed consistently as the trailing P/E divided by that growth rate — reported earnings, never an expected-earnings multiple. On Indian companies it is shown only where the two data feeds agreed. Where any of that fails the ratio is left out rather than printed: a P/E divided by a loss, or by growth measured off a tiny base, is a number that looks precise and means nothing.
PEGlowest PEG
P/Elowest P/E
Valuation · company comparison
1/3 level · 3/3 change
All-company data · latest reported quarter
| Company | PEG | P/E | Reported |
|---|---|---|---|
| Rossari Biotech Ltd ROSSARI | 1.7 | 19.9 | Jun 2026 |
| Advanced Enzyme Technologies Ltd ADVENZYMES | — | 20.7 | Mar 2026 |
| Bombay Super Hybrid Seeds Ltd BSHSL⚠ unverified | — | 26.7 | Mar 2026 |
Full 20-quarter history · every available company
PEG · reported quarter history
Rossari Biotech Ltd · ROSSARI
4.9
2.5
2.1
3.2
5.7
—
6.4
4.8
7.3
2.2
1.7
1.6
1.4
1.7
—
—
—
—
—
—
P/E · reported quarter history
Advanced Enzyme Technologies Ltd · ADVENZYMES
28.4
25.6
25.9
25.1
30.3
32.7
26.5
28.8
30.0
32.9
27.8
29.9
38.0
26.7
21.9
28.1
26.1
22.5
20.7
—
Bombay Super Hybrid Seeds Ltd · BSHSL⚠ unverified
31.2
34.1
38.3
40.1
99.0
194.4
237.2
173.7
128.9
135.2
111.2
90.5
82.9
65.9
50.1
57.0
50.0
41.9
26.7
—
Rossari Biotech Ltd · ROSSARI
86.9
72.5
52.6
48.5
52.5
40.3
32.1
44.8
41.7
37.8
29.8
35.6
37.1
31.7
24.6
27.7
25.8
23.3
16.0
19.9
11 · before the conclusion, check the blind spots
What can make this comparison misleading?
This Seeds/Tissue Culture/Bio Technology comparison names 7 specific ways its own evidence can mislead, all listed below. All 3 companies here report on comparable dates, so no rank carries a stale marker. 1 draws at least one figure from a second feed with too little overlap to cross-check. 1 has second-feed figures withheld because the two sources disagree.
Keep these limits visible
- A high growth rate can be a low-base artefact. The page keeps level and change separate for that reason.
- A high ROCE can be temporary or flattered by a small capital base. Read it beside margin, cash conversion and reinvestment.
- The 4-Factor Sector Score ranks research priority, not portfolio action. Management quality, catalysts and risks need equally fresh evidence before capital is deployed.
- An “all companies” line chart preserves completeness, but rank changes should be checked against reporting dates before drawing a conclusion.
- 1 company draws at least one figure from a second data feed with too little overlapping history to cross-check against the primary source; it is marked unverified wherever that figure appears.
- 1 company is missing from the second-feed metrics by decision, not by absence: the two sources disagree, so nothing from the second is drawn. Read those rows as narrower evidence, never as a weaker business.
- Thin comparisons: Valuation have fewer than three usable current readings.
12 · evidence and freshness
How was this comparison built?
This comparison is built from the reported filings of 3 Seeds/Tissue Culture/Bio Technology companies, normalized to a common ₹ scale and a shared quarter axis of up to 20 quarters each. Fundamentals run through Jun 2026 and market data through 2026-07-31. A second data feed fills gaps only after identity and scale reconciliation, and missing observations are never interpolated.
FundamentalsThrough Jun 2026 · up to 20 quarters per company
Market dataThrough 2026-07-31 · weekly price and relative-strength history
Derived metricsGrowth, changes and PEG are calculated only when their inputs are comparable.
Score confidenceMissing and stale evidence reduces confidence and pulls the 0–100 research-priority score toward neutral.
Source standing1 cross-checked · 1 unverified · 1 withheld, of 3 graded companies.
How a second data feed is admitted, and what happens when it disagrees
A second feed is read only after its reported income is matched against the primary source on at least three overlapping periods. Where the two agree the figures fill silently. Where there is too little shared history to compare, the figures are still drawn — they are the only evidence there is — and marked ⚠ unverified everywhere they appear. Where the two are known to disagree, nothing from the second feed is drawn and the affected company is named under the chart it is missing from.
13 · questions investors ask, short speakable answers
Seeds/Tissue Culture/Bio Technology company comparison FAQs
These 23 answers restate the Seeds/Tissue Culture/Bio Technology comparison above in question form. Every one is computed from the same 3 companies and the same reported filings as the rankings and charts, current through Jun 2026. Price and relative-strength answers run through 2026-07-31. Nothing here is estimated, and none of it is a recommendation.
Is the Seeds/Tissue Culture/Bio Technology sector outperforming NIFTY 500?
Seeds/Tissue Culture/Bio Technology has underperformed NIFTY 500 by 31.9% over 52 weeks and 7% over 13 weeks. 0 of 3 covered companies beat NIFTY on Mansfield relative strength, while 2 of 3 beat the sector itself.
Which Seeds/Tissue Culture/Bio Technology company is largest by revenue?
Rossari Biotech Ltd leads with revenue of ₹2,550 crore, based on 3 of 3 comparable companies through Jun 2026.
Which Seeds/Tissue Culture/Bio Technology company is growing fastest?
Rossari Biotech Ltd has the fastest current revenue growth at 19.4%, across 3 of 3 comparable companies.
Which Seeds/Tissue Culture/Bio Technology company has the strongest 4-Factor Sector Score?
Advanced Enzyme Technologies Ltd ranks first at 65.8/100 with 75.1% evidence confidence. The score prioritizes research; it is not a buy recommendation.
Which Seeds/Tissue Culture/Bio Technology company has the lowest comparable PEG?
Rossari Biotech Ltd has the lowest comparable PEG at 1.7, among 1 of 3 companies whose earnings and growth are steady enough for the ratio to mean anything.
How much history does this Seeds/Tissue Culture/Bio Technology comparison include?
The page compares up to 20 reported quarters per company for fundamentals, returns and valuation, ending Jun 2026. Missing observations remain blank rather than being estimated.
How is the 4-Factor Sector Score calculated?
The four visible contributions add directly: growth and earnings up to 35 points, capital efficiency up to 25, valuation up to 20, and relative strength up to 20. Missing or stale evidence moves only the affected contribution toward neutral.
What is the Nifty Seeds/Tissue Culture/Bio Technology index?
The Nifty Seeds/Tissue Culture/Bio Technology index tracks India's listed Seeds/Tissue Culture/Bio Technology companies as a single basket. This page follows the same 3 companies and equal-weights them, so every company's weekly return counts once whatever it is worth, and the reading belongs to the Seeds/Tissue Culture/Bio Technology sector rather than to its largest constituent. Figures are as of Jun 2026.
Which are the best Seeds/Tissue Culture/Bio Technology stocks in India?
Ranked by this page's four-factor score, Advanced Enzyme Technologies Ltd places first among 3 listed Seeds/Tissue Culture/Bio Technology companies, followed by Rossari Biotech Ltd. That is a ranking of published data — earnings, quality, valuation and market behaviour as of Jun 2026 — and not a recommendation; Sector Alpha is not registered with SEBI as an investment adviser.
How many Seeds/Tissue Culture/Bio Technology stocks are listed in India?
This comparison covers 3 listed Seeds/Tissue Culture/Bio Technology companies in India, each above the size floor the site applies, with 20 quarters of reported figures per company where the filings exist. The full ranked list is on this page, as of Jun 2026.
Which Seeds/Tissue Culture/Bio Technology company is the biggest?
Rossari Biotech Ltd is the largest, with trailing-twelve-month revenue of ₹2,550 crore, ahead of Advanced Enzyme Technologies Ltd at ₹746 crore. That covers 3 of 3 companies with comparable reporting through Jun 2026.
Which Seeds/Tissue Culture/Bio Technology company has the best profit margins?
Advanced Enzyme Technologies Ltd has the highest operating margin at 31%, from 3 of 3 comparable companies. Advanced Enzyme Technologies Ltd shows the biggest recent improvement, at +4 percentage points. A high margin matters most when it is holding or rising, not when it is peaking.
Which Seeds/Tissue Culture/Bio Technology company makes the most profit?
Advanced Enzyme Technologies Ltd earns the most, at ₹173 crore of trailing-twelve-month net profit, from 3 of 3 comparable companies. Advanced Enzyme Technologies Ltd has the fastest profit growth at 29.1%, though growth off a small or recovering profit base overstates how much has actually changed.
Which Seeds/Tissue Culture/Bio Technology company earns the highest return on capital?
Bombay Super Hybrid Seeds Ltd leads on return on capital employed at 16%, across 3 of 3 companies. Read it beside the length of its reported history: a high return that repeats for years is evidence of a durable business, while a single high reading can be a small capital base or one good year.
Which Seeds/Tissue Culture/Bio Technology stock is the cheapest?
On PEG — where a LOWER number is cheaper — Rossari Biotech Ltd screens cheapest at 1.7×. Only 1 of 3 companies have earnings and growth steady enough for the ratio to mean anything, so this is not a sector-wide "cheapest stock" verdict. Cheap on a multiple is a reason to investigate, never a reason to buy on its own.
Is the Seeds/Tissue Culture/Bio Technology sector beating the market?
Seeds/Tissue Culture/Bio Technology has underperformed NIFTY 500 by 31.9% over the last 52 weeks and 7% over 13 weeks, measured on an equal-weight index of its current members. Inside the sector, 0 of 3 covered companies are beating the market on their own. Sector strength does not transfer evenly to every stock in it.
Which Seeds/Tissue Culture/Bio Technology stock has the strongest price momentum?
Advanced Enzyme Technologies Ltd has the strongest relative strength against NIFTY 500. Relative strength answers last, after growth, quality and valuation: price can move well before the fundamentals confirm it, and sometimes without them confirming at all.
Which Seeds/Tissue Culture/Bio Technology company scores highest for research priority?
Advanced Enzyme Technologies Ltd scores 65.8 out of 100 with 75.1% evidence confidence, from 27.8 points on growth and earnings, 15.5 on capital efficiency, 12 on valuation and 10.5 on relative strength. This ranks what deserves work next. It is not a buy recommendation, and management quality, catalysts and risk still need separate research.
How many Seeds/Tissue Culture/Bio Technology companies does this comparison cover, and over what period?
It compares 3 listed companies over up to 20 reported quarters of fundamentals, ending Jun 2026, plus weekly price and relative-strength history. Membership is the full sector list — nothing is dropped for having thin data.
What is the total market cap of the Seeds/Tissue Culture/Bio Technology sector?
The 3 Seeds/Tissue Culture/Bio Technology companies on this page carry ₹7,214 crore of combined market value. Advanced Enzyme Technologies Ltd is the largest at ₹3,528 crore, about 49% of the sector's total on its own. Market value moves with price, so this reading is dated 2026-08-05.
How is the Seeds/Tissue Culture/Bio Technology sector performing?
0 of the 3 covered Seeds/Tissue Culture/Bio Technology companies are beating NIFTY 500 on Mansfield relative strength. The sector itself is 31.9% behind NIFTY 500 over 52 weeks on an equal-weight index of its current members. Readings are as of 2026-08-05.
Why are some values on this page blank?
A blank means that company did not report a comparable figure for that period, so nothing is shown. Missing observations are never interpolated, carried forward, or replaced with a similar-looking accounting line, and a company with missing evidence has its research score pulled toward neutral rather than being scored as bad.
Is this investment advice?
No. Every figure here is a deterministic calculation from reported company filings and market data, published for research. It contains no recommendation to buy or sell any security, does not account for your circumstances, and is not a substitute for advice from a licensed adviser.